4 结语
胰岛素抵抗可导致多种疾病，因此，研究胰岛素抵抗的机制十分重要。PPARs是噻唑烷二酮类药物(TZDs)治疗胰岛素抵抗的作用靶点〔1〕。该类药物能激活PPARγ，从而减少FFA和TNF-α的释放及增加脂联素的分泌来调节脂肪组织的发育及代谢。此外，PPARα调节游离脂肪酸氧化的能力暗示了这一受体的激活机制治疗胰岛素抵抗的潜能。实验研究指出〔18〕，PPARα的激活还能显著降低心血管疾病的发生率。显然，研究PPARs在治疗和预防胰岛素抵抗中的机制有着重要的学术价值和临床应用前景。
【参考文献】
〔1〕 Minghan Wang，Sherrie Tafuri.Modulation of PPARγ activity with pharmaceutical agents：treatment of insulin resistance and atherosclerosis［J］.Journal of Cellular Biochemistry,2003,89：38-47.
〔2〕 Nguan Soon Tan,Liliane Michalik，Beatrice Desvergne Multiple expression control mechanisms of peroxisome proliferater-activated receptors and their genes［J］.Journal of Steroid Biochemistry & Molecular Biology,2005,93：99-105.
〔3〕 L E Fridly,L H Philipson.Reactive species and early manifestation of insulin resistance in type 2 diabetes［J］.Diabetes Obesity and Metabolism，2005，1463-1326.
〔4〕 P Peter,S L Nuttall，M J Kendall.Insulin resistance-the new goal［J］.Journal of Clinical Pharmacy and Therapeutics,2003,28：167-174.
〔5〕 Malarvannan Pannirselvam，Todd J Anderson，Chris R Triggle，et al.Endothelial cell dysfunction in type I and II diabetes：the cellular basis for dysfunction［J］.Drug Development Research，2003，58：28-41.
〔6〕 Daniel E Rosenberg，Serge A Jabbour,Barry J Goldstein,et al.Insulin resistance，diabetes and cardiovascular risk：approaches to treatment［J］.Diabetes Obesity and metabolism，2005，7：642-653.
〔7〕 KS Vimaleswaran，V Radha，S Ghosh.Peroxisome proliferator-activated receptor-γ coactivator-l α(PGC-lα)gene polymorphisms and their relationship to Type 2 diabetes in Asian Indians［J］.Journal of Clinical Laboratory Analysis,2004，18：317-321.
〔8〕 L E Fridly，L H Philipson.Reactive species and early manifestation of insulin resistance in type 2 diabetes［J］.Diabetes，Obesity and Metabolism，2006,8(2):136-145.
〔9〕 Andersen LB，Harro M，Sardinha LB，et al.Physical activity and clustered cardiovascular risk in children：a cross-sectional study(The European Youth Heart Study)［J］.Lancet,2006，368(9532)：299-304.
〔10〕 Harold E Lebovitz.Insulin resistance-a common link between type 2 diabetes and cardiovascular disease［J］.Diabetes，Obesity and Metabolism，2006,8(3):237-249.
〔11〕 Ulrika Edvardsson，Helena Brockenhuus，Oleg Panfilov，et a1.Hepatic protein expression of lean mice and obese diabetic mice treated with peroxisome proliferator-activated receptor activators［J］.Proteomics，2003,3：468-478.
〔12〕 Tok E C，Aktas A，Erdal E M，et al.Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator activated receptor(PPAR)一γ2 Prol2Ala genotype［J］.Human Reproduction,2005，20(6)：1590-1595.
〔13〕 Loria P，Lonardo A,Carulli L.Review article：the metabalic syndrome and non-alcoholic fatty liver disease［J］.Aliment Pharmacol Ther,2005,22(S2)：31-36.
〔14〕 Gervois P，Fruehart J C，Staels B，et al.Inflammation，dyslipidaemia,diabetes and PPARs：pharmacological interest of dual PPAR α and PPAR γ［J］.Agonists，2004，58：22-29.
〔15〕 Yalverde AM，Benito2 M，Lorenzo M.The brown adipose cell：a model for understanding the molecular mechanisms of insulin resistance［J］.Acta Physiol Scand，2005，183：59-73.
〔16〕 Motohiro Sekiya，Naoya Yahagi，Takashi Matsuzak,et al.Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 Suppression［J］.Hepatology，2003，38(6)：1529-1539.
〔17〕 Jussi Pihlajsmaki，Mauno Vanhala，Pasi Vanhala,et al.The Prol2Ala Polymorphism of the PPAR γ 2 Gene.Regulates weight from birth to adulthood［J］.Obesity Research，2004，12(2)：187.190.
〔18〕 Gervois P，Fruchart J C，Staels B，et a1.Inflammation,dyslipidaemia,diabetes and PPARs：pharmacological interest of dual PPAR α and PPAR γ agonists［J］.Int J Clin Pract Suppl，2004，143：22-29.
